? CANCER BIOLOGY (CB) The Cancer Biology (CB) Program at The Ohio State University Comprehensive Cancer Center (OSUCCC), led by Matthew Ringel, MD, and Philip Tsichlis, MD, has 56 members from 21 Departments and 5 OSU Colleges (Arts & Sciences, Engineering, Medicine, Public Health, and Veterinary Medicine). CB investigators focus on three thematic scientific areas of focus: 1) Defining the roles of non-coding RNAs, gene mutations, and regulation of gene expression in cancer development and progression; 2) Determining new mechanisms of altered cancer cell signal transduction and DNA damage repair responses, and responses to therapeutic challenges; and 3) integrating cancer biology into complex model systems, computational biology, and human tissues to study mechanisms of cancer progression. The overall vision of the CB Program is to exploit the fundamental mechanistic knowledge gained in these areas of strategic emphasis to improve cancer prevention, treatment, and outcomes through collaborations.
The Specific Aims of the CB Program focus on: 1) Mechanisms of cancer initiation. Studies focus on identification and characterization of mutations, epigenetic changes, and the expression and function of coding and non-coding genes. The goal will be to discover novel mechanisms of cancer predisposition and initiation, with an emphasis on translation; 2) Mechanisms and markers of response and resistance to therapeutic and environmental challenges. Research focuses on cancer responses to radiation and chemotherapy/targeted therapy with emphasis on signaling, DNA damage and the response to hypoxia and anti-tumor immunity; and, 3) Mechanisms of cancer progression. Studies focus on the identification of potentially targetable mechanisms that regulate tumor progression and metastasis. CB Program members published 645 cancer-relevant manuscripts between 12/01/14 and 11/30/19. Of these, 10% were intra- programmatic (multiple authors from CC Program), 25% were inter-programmatic (authors from multiple OSUCCC Programs), and 73% were multi-institutional (authors from both CB and another institution). The total collaborative publications is 81%. CB Program funding stands at $8.0M in overall direct, cancer-focused funding, of which $7.7M is peer-reviewed, including $6.7M direct funding from NIH ($5.1M from NCI). Over the last 5 years, CB Program members have accrued 1,522 participants to non-therapeutic/non-interventional trials comprised of investigator-driven IRB-approved biospecimen repositories. As a basic science program, CB is designed for member involvement in therapeutic trials through inter-programmatic collaboration. Future plans for the CB Program include innovation and growth in cancer immunology, translational genomics leveraging inter-institutional resources such as ORIEN, and identification of new targets, the development and growth of the cancer engineering research, and for cancer prevention by increasing basic science studies for the development of cancer and genetic predispositions.
|Zhang, Tianyu; Xu, Jielin; Deng, Siyuan et al. (2018) Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data. PLoS One 13:e0196351|
|Yang, Zhifen; Zhang, Jing; Jiang, Dadi et al. (2018) A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1?-XBP1 Activation. Mol Cancer Res 16:745-753|
|LaPak, Kyle M; Vroom, Dennis C; Garg, Ayush A et al. (2018) Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways. Oncotarget 9:25386-25401|
|Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035|
|Kaffenberger, Benjamin H; Hinton, Alice; Krishna, Somashekar G (2018) The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. J Am Acad Dermatol 79:659-663.e2|
|Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55|
|Rahnemai-Azar, Amir A; Cloyd, Jordan M; Weber, Sharon M et al. (2018) Update on Liver Failure Following Hepatic Resection: Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency. J Clin Transl Hepatol 6:97-104|
|Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620|
|Kodigepalli, Karthik M; Bonifati, Serena; Tirumuru, Nagaraja et al. (2018) SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle 17:1124-1137|
|Wang, Zhilian; Li, Zaibo; Li, Jing et al. (2018) Prevalence and Distribution of HPV Genotypes in 1387 Women with Cervical Intraepithelial Neoplasia 2/3 in Shanxi Province, China. J Cancer 9:2802-2806|
Showing the most recent 10 out of 2602 publications